Noopept vs Semax vs Selank is the essential comparison for researchers studying cognitive enhancement, neuroprotection, and anxiolysis through peptide-based mechanisms. All three compounds were developed in Russian research institutions, all have regulatory approval in Russia for neurological applications, and all represent distinct approaches to brain function modulation. Noopept enhances glutamatergic signaling through AMPA/NMDA receptor modulation and neurotrophic factor upregulation. Semax promotes neuroplasticity through BDNF (brain-derived neurotrophic factor) elevation and melanocortin receptor activation. Selank reduces anxiety through GABAergic modulation and enkephalinase inhibition without sedation. Despite being grouped together as “nootropics,” their mechanisms are as different as their applications — and choosing the wrong one for your research question will produce the wrong data.

PSPeptides carries all three: Noopept Tablets, Semax Nasal Spray, Selank Nasal Spray, and the Selank+Semax combination spray. See our individual guides: Semax, Selank, and our Semax vs Selank comparison.

Noopept vs Semax vs Selank: Complete Comparison

Noopept: Memory and Learning Enhancement

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a dipeptide-derived nootropic that enhances glutamatergic neurotransmission through modulation of AMPA and NMDA receptors — the excitatory receptor systems that underlie synaptic plasticity, long-term potentiation (LTP), and memory formation. Published research has demonstrated that Noopept increases the expression of both NGF (nerve growth factor) and BDNF in the hippocampus and cortex — the brain regions most critical for memory encoding and consolidation.

Noopept’s cognitive enhancement profile centers on memory consolidation (converting short-term into long-term memory), learning speed (rate of new information acquisition), and neuroprotection against oxidative damage and amyloid aggregation. The AMPA receptor modulation is particularly significant — published pharmacological research classifies Noopept as an AMPA receptor-positive modulator, meaning it enhances AMPA receptor function without directly activating the receptor. This subtle distinction avoids the excitotoxicity risk of direct glutamate agonism while strengthening the efficiency of neural circuit communication underlying learning. The NMDA receptor modulation supports the calcium-dependent signaling cascades that convert short-term synaptic changes into stable long-term memories through structural synaptic modification. Unlike Selank, Noopept does not have primary anxiolytic effects — it enhances cognitive performance directly rather than indirectly through anxiety reduction. Noopept also demonstrates neuroprotective properties through antioxidant mechanisms and anti-amyloid effects — published research shows it reduces oxidative stress markers and attenuates amyloid-beta aggregation, the protein accumulation associated with Alzheimer’s pathology. PSPeptides’ Noopept Tablets provide convenient oral delivery — Noopept’s small molecular weight (318 Da) and oral bioavailability make tablet delivery practical without nasal or injectable administration.

Semax: Neuroplasticity and BDNF

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for its neurotropic effects while lacking the hormonal activity (cortisol stimulation) of the full ACTH molecule. Published research demonstrates that Semax robustly elevates BDNF expression in the hippocampus, cortex, and basal forebrain — the neurotrophic factor most directly linked to synaptic plasticity, learning, and memory.

Beyond cognitive enhancement, Semax has an approved indication in Russia for ischemic stroke recovery — making it one of the only nootropic peptides with clinical data for structural neuroprotection in acute brain injury. The stroke recovery mechanism involves BDNF-mediated neuronal survival in ischemic penumbra tissue (the brain region surrounding the infarct core that is damaged but potentially salvageable), VEGF-mediated angiogenesis supporting revascularization of ischemic brain tissue, anti-inflammatory modulation reducing microglial overactivation in the peri-infarct region, and promotion of neuroplastic reorganization during recovery. This multi-pathway neuroprotective profile — simultaneously addressing neuronal survival, vascular repair, inflammation, and plasticity — explains why Semax earned regulatory approval for stroke recovery rather than just cognitive enhancement. The intranasal delivery format provides rapid brain access through nose-to-brain transport, which is particularly relevant for acute neurological conditions where speed of drug delivery matters. PSPeptides’ Semax Nasal Spray matches the clinical delivery format used in the Russian approval. For more detail, see our Semax guide.

Selank: Non-Sedating Anxiolysis — A Qualitatively Different Approach

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analogue of tuftsin — an endogenous immunomodulatory tetrapeptide — with a Pro-Gly-Pro extension that enhances CNS activity and metabolic stability. Selank’s primary mechanism involves modulation of GABAergic neurotransmission — the inhibitory system that regulates anxiety, stress response, and neural excitability — and inhibition of enkephalinase, the enzyme that degrades endogenous anxiolytic peptides (enkephalins). By preserving endogenous enkephalin levels, Selank extends the activity of the body’s own anti-anxiety signaling system rather than introducing an exogenous sedative.

Selank’s defining advantage is its anxiolytic profile: it reduces anxiety comparably to benzodiazepines in published research but without sedation, cognitive impairment, or dependence liability. This distinction is pharmacologically profound. Benzodiazepines (diazepam, alprazolam, lorazepam) work by allosterically enhancing GABA-A receptor activity throughout the brain — producing anxiety reduction but also drowsiness, impaired memory formation, motor coordination deficits, and physical dependence with chronic use. Selank modulates GABAergic tone through a different mechanism — one that produces anxiolysis while preserving the cognitive processes that benzodiazepines impair. Published research confirmed that Selank-treated subjects maintained cognitive performance scores equal to or better than baseline during anxiolytic treatment — a result benzodiazepines cannot produce.

This non-sedating anxiolysis makes Selank the appropriate choice when anxiety is the primary research variable or when anxiety reduction is a prerequisite for accurate cognitive testing — if anxiety impairs a subject’s cognitive performance, measuring true cognitive potential requires resolving the anxiety first. Selank resolves the anxiety without introducing cognitive impairment that would confound the subsequent cognitive measurement. PSPeptides’ Selank Nasal Spray provides intranasal delivery with nose-to-brain transport for direct CNS access. For more detail, see our Selank guide.

Choosing by Research Goal

Memory and learning research: Noopept — direct glutamatergic enhancement of synaptic plasticity mechanisms. Neuroplasticity and recovery: Semax — BDNF-mediated neuroprotection and neuroplastic reorganization. Anxiety and stress research: Selank — GABAergic anxiolysis without cognitive impairment. Combined cognitive+anxiety: Selank+Semax blend — Selank reduces the anxiety that impairs cognitive testing, Semax enhances the cognitive processes being tested. Comprehensive nootropic protocol: All three — Noopept (tablets daily) + Semax+Selank (nasal spray daily) for glutamatergic, BDNF, and GABAergic coverage simultaneously. For the broader cognitive peptide landscape, see our cognitive enhancement guide.

Why Combining All Three Is Mechanistically Sound

The rationale for using Noopept, Semax, and Selank together rests on neurotransmitter system non-overlap. Each compound modulates a different primary neurotransmitter system — glutamate (Noopept), BDNF/melanocortin (Semax), and GABA/enkephalin (Selank). These systems interact but are not redundant, meaning stimulating all three simultaneously produces broader cognitive support than maximizing any single pathway.

Glutamatergic enhancement (Noopept) increases the raw capacity for synaptic plasticity and memory encoding — but excessive glutamate without adequate inhibitory balance can produce anxiety and neural excitotoxicity. GABAergic modulation (Selank) provides that inhibitory balance — maintaining the calm, focused state that optimizes cognitive performance while preventing the anxiety that impairs memory retrieval and decision-making. BDNF elevation (Semax) supports the structural neuroplastic changes — dendritic branching, synaptic strengthening, neurogenesis — that consolidate the learning Noopept facilitates.

The practical implementation is straightforward: Noopept Tablets (oral, morning administration) provide all-day glutamatergic support, while the Selank+Semax combination spray (intranasal, morning or as needed) provides combined BDNF elevation and anxiolysis through a single spray device. This three-compound protocol addresses cognitive enhancement from the excitatory, inhibitory, and neurotrophic dimensions simultaneously — a comprehensive approach that no single nootropic compound can match. The daily workflow is minimal: take one Noopept tablet orally with breakfast (10 seconds), administer the Selank+Semax combination spray intranasally (30 seconds). Total daily administration time is under one minute for a three-mechanism cognitive support protocol — compared to the 5-10 minutes per compound that injectable preparation would require. For extended cognitive research protocols lasting weeks or months, this convenience difference directly impacts compliance rates and therefore data quality. The spray plus tablet combination also eliminates the needle and sterile technique requirements that might limit participation in cognitive research studies where subjects self-administer.

Delivery Format and the Nose-to-Brain Advantage

An important practical distinction: Noopept is orally bioavailable and is delivered as tablets, while Semax and Selank are delivered intranasally as sprays. This is not arbitrary — it reflects the optimal delivery route for each compound’s mechanism. Noopept’s small-molecule structure (MW 318 Da) crosses the blood-brain barrier efficiently from systemic circulation after oral absorption, making tablet delivery practical. Semax and Selank are larger heptapeptides (MW ~800-900 Da) that benefit from the nose-to-brain pathway — direct neural transport via olfactory and trigeminal nerve pathways that bypass the BBB entirely and deliver the peptides directly to brain tissue within minutes.

The nasal spray format for Semax and Selank matches the clinical delivery route used in their Russian regulatory approvals — meaning the delivery format with the most extensive clinical safety and efficacy validation data is the same format PSPeptides provides. This alignment between the research product and the clinically validated delivery route gives researchers confidence that the format they are using has been tested in controlled human studies rather than extrapolated from animal data using a different route. For a broader comparison of nasal spray versus injectable delivery, see our spray vs injectable guide.

Safety Profiles and Clinical Validation

All three compounds have regulatory approval in Russia — a level of clinical validation that distinguishes them from most research peptides, which rely entirely on preclinical evidence. However, the depth and nature of their clinical validation differs.

Noopept was approved in Russia as a nootropic based on clinical studies demonstrating cognitive improvement in patients with organic brain disorders and age-related cognitive decline. Published safety data from these clinical programs shows Noopept is well-tolerated at recommended oral doses with no significant adverse effects on cardiovascular, hepatic, or renal function. The most commonly reported effects are mild headache (typically transient and dose-related) and occasional sleep disturbance when taken too late in the day — consistent with its excitatory glutamatergic mechanism. Noopept does not produce the tolerance, dependence, or withdrawal effects associated with stimulant-class cognitive enhancers.

Semax has the strongest clinical validation — approved for both cognitive enhancement and ischemic stroke recovery, with the stroke indication requiring Phase 3-level clinical data demonstrating efficacy in a life-threatening neurological condition. The clinical safety database for Semax is the largest of the three compounds. Intranasal administration produces minimal systemic side effects — the most common is transient nasal irritation. Published long-term safety data from post-market surveillance supports extended use without tolerance development or significant adverse events.

Selank was approved as an anxiolytic based on clinical trials comparing its efficacy and side effect profile to benzodiazepines. The pivotal finding was that Selank produced comparable anxiety reduction without the sedation, cognitive impairment, tolerance, or dependence that limit benzodiazepine use. Published safety data confirms no withdrawal syndrome, no rebound anxiety, and no tolerance development with extended use — distinguishing Selank from every classical anxiolytic medication. The intranasal delivery format produces minimal systemic effects beyond the intended anxiolysis.

Dosing and Practical Protocol Design

For practical multi-compound protocols, timing and sequencing matter. Noopept’s oral bioavailability means it can be taken with or without food, though some researchers report slightly better subjective effects on an empty stomach. Morning administration is typical because Noopept’s glutamatergic enhancement supports daytime cognitive demands, and late-day dosing can interfere with sleep onset. The PSPeptides Noopept Tablets provide calibrated oral doses for consistent daily administration.

Semax and Selank nasal sprays can be administered at any time — the nose-to-brain delivery produces effects within minutes, making them suitable for both scheduled daily dosing and as-needed situational use (before presentations, exams, or high-stress cognitive tasks). The Selank+Semax combination spray simplifies the protocol to a single spray device delivering both compounds. Store all sprays at 2-8°C per our storage guide. For researchers comparing nasal vs injectable delivery for these peptides, see our spray vs injectable guide.

The Immune Dimension: Selank’s Tuftsin Heritage

One underappreciated aspect of the Noopept vs Semax vs Selank comparison is Selank’s immune-modulating dimension. Selank is derived from tuftsin — an endogenous immunomodulatory tetrapeptide that activates phagocytic cells (macrophages, neutrophils). Published research shows Selank modulates the expression of over 40 inflammation-related genes and influences T-helper cell balance (Th1/Th2 ratio). This neuroimmune dual activity — anxiolysis plus immune modulation — reflects the growing scientific recognition that the nervous and immune systems are deeply interconnected through neuroimmune signaling pathways. Researchers studying the intersection of stress, immunity, and cognition may find Selank’s dual neuroimmune mechanism uniquely relevant. For immune-focused peptides, our immune support guide covers Thymosin Alpha-1 and other immunomodulatory compounds. The neuroimmune dimension also means that Selank’s anxiolytic effects may partially involve immune system modulation — chronic stress activates inflammatory immune pathways that contribute to anxiety through neuroinflammation, and Selank’s immune-modulatory activity may dampen this stress-inflammation-anxiety cycle at both the neural and immune levels simultaneously. This mechanistic breadth distinguishes Selank from both Noopept (purely neuronal mechanism) and Semax (primarily neurotrophic mechanism), positioning it as the most pharmacologically complex member of the Russian nootropic trio — a compound that operates at the intersection of neuroscience and immunology rather than within either field alone. This positioning is increasingly relevant as the field of psychoneuroimmunology — studying the bidirectional interactions between psychological processes, the nervous system, and immune function — gains recognition as a critical dimension of both mental health and cognitive performance research. For researchers studying peptides that bridge neural and immune function, our KPV guide covers NF-kB-mediated anti-inflammatory signaling that also intersects with neuroimmune pathways.

Understanding noopept vs semax vs selank is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is the difference between Noopept, Semax, and Selank?

Noopept enhances memory formation and learning speed through AMPA/NMDA glutamate receptor modulation — strengthening the excitatory synaptic transmission that underlies long-term potentiation and memory consolidation. Semax promotes neuroplasticity and neuroprotection through robust BDNF elevation — supporting structural synaptic changes including dendritic branching and synaptogenesis. Selank reduces anxiety through GABAergic modulation and enkephalinase inhibition without sedation or cognitive impairment — a qualitatively different anxiolytic mechanism from benzodiazepines. Three different neurotransmitter systems for three different cognitive dimensions, making them complementary rather than redundant.

Which is best for anxiety?

Selank. It produces non-sedating anxiolysis comparable to benzodiazepines without the cognitive impairment, drowsiness, or dependence liability. It is the only one of the three with primary anxiolytic activity.

Can I combine all three?

Yes. Their mechanisms are non-overlapping — Noopept (glutamatergic), Semax (BDNF), and Selank (GABAergic) address different neurotransmitter systems. PSPeptides offers Noopept Tablets plus the Selank+Semax combination spray for a practical three-compound protocol that covers glutamatergic, BDNF-mediated, and GABAergic cognitive support simultaneously with minimal daily administration overhead.

Which delivery format does each use?

Noopept: oral tablets (PSPeptides). Semax and Selank: nasal sprays (PSPeptides) — matching the clinical delivery format. The nasal route provides nose-to-brain delivery that bypasses the blood-brain barrier for direct CNS access.

All PSPeptides products are sold exclusively for research and laboratory use.